Novel Antibody-Drug Conjugate Shows Efficacy in Advanced EGFR-Mutated NSCLC

(MedPage Today) -- SINGAPORE -- Treatment with the novel antibody-drug conjugate patritumab deruxtecan (HER3-DXd) after progression with an EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy resulted in "clinically meaningful...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news